SOUTH SAN FRANCISCO, Calif. , Aug. 06, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced that its management team will participate in the following investor conferences in the month of August: Canaccord Genuity 44 th Annual Growth Conference on August 13 th , 2024
Alex Kim , Chief Operating Officer and Standard BioTools Co-Founder, to Serve as interim Chief Financial Officer Following Departure of Jeffrey Black on August 31, 2024 Industry Veteran Sean Mackay Named Chief Business Officer SOUTH SAN FRANCISCO, Calif.
Delivered revenue of $37.2 million Accelerated merger synergies with $80 million expected to be operationalized in 2024 Revised FY2024 revenue guidance; on-track to achieve anticipated break-even adjusted EBITDA for full-year 2026 Current balance sheet of $396 million cash, cash equivalents,
SOUTH SAN FRANCISCO, Calif. , July 17, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report second quarter 2024 financial results on Wednesday, July 31, 2024, after the close of the market.
SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY , May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSA XT system from Carterra ® , a leading provider of high-throughput large and small molecule screening and characterization solutions.
SOUTH SAN FRANCISCO, Calif. , May 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today announced that its management team will participate in the following investor conferences in the month of June: Jefferies Global Healthcare Conference on June 5 th & 6 th
SOUTH SAN FRANCISCO, Calif. , May 20, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today announced that the Human Capital Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of May 20,
Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025 Delivered pro forma combined revenue of $46.2 million , gross margin of 49.2%, non-GAAP gross margin of 56.3%, operating expense reduction of
Company expects to achieve $45-$50 million in annualized operating expense savings in fiscal 2025 Management to discuss first quarter 2024 financial results, restructuring and strategic initiatives on May 8, 2024 conference call SOUTH SAN FRANCISCO, Calif.
SOUTH SAN FRANCISCO, Calif. , April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the market.
